A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (NCT04065399)
A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation
🩺 Plain-English Summary (8th-Grade Level)
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.
Who can join: Review the eligibility criteria below.
Location: City of Hope Comprehensive Cancer Center — Duarte, California
Age range: 30 Days
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (57 Sites)
Showing the first 25 of 57 sites.
- City of Hope Comprehensive Cancer Center — Duarte, California
- University Of California Care Medical Group - Norris Comprehensive Cancer Center And Hospital — Los Angeles, California
- Stanford Cancer Institute — Palo Alto, California
- University of Colorado — Aurora, Colorado
- Florida Cancer Specialists and Research Institute — Sarasota, Florida
- Moffitt Cancer Center — Tampa, Florida
- Emory Winship Cancer Institute — Atlanta, Georgia
- Children's Healthcare of Atlanta — Atlanta, Georgia
- The University of Chicago Medical Center — Chicago, Illinois
- University of Iowa Hospital — Iowa City, Iowa
- Dana Farber Cancer Institute — Boston, Massachusetts
- Washington University in St. Louis School of Medicine — St Louis, Missouri
- Hackensack University Medical Center — Hackensack, New Jersey
- Memorial Sloan Kettering Cancer Center — New York, New York
- Montefiore Medical Center — New York, New York
- Duke University Medical Center — Durham, North Carolina
- University of Cincinnati — Cincinnati, Ohio
- Ohio State University — Columbus, Ohio
- Oregon Health & Science University — Portland, Oregon
- University of Pennsylvania — Philadelphia, Pennsylvania
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah
- Peter MacCallum Cancer Centre (PMCC) — Melbourne, Victoria
- Royal Melbourne Hospital (RMH) — Parkville, Victoria
- Alfred Hospital — Melbourne,
📞 Contact the Study Coordinator
Phone: (781) 419-1400
Email: clinicaltrials@syndax.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukemia
- PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS — Tampa, Florida
- Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT — Tampa, Florida
- Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy — Little Rock, Arkansas
- Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia — Burbank, California
- A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies — Duarte, California
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia — Madera, California
Explore by condition: All Acute Myeloid Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.